Cefixime and Ofloxacin fixed dose combination induced petechial rash: a case report

Sudhir Kumar, Kirti Nirmal, Amit Kumar Nirmal, S. K. Bhattacharya


Petechial rash is a type of rash which is associated with many infectious and non-infectious conditions. We present a case of Petechial rash induced by administration of cefixime with ofloxacin tablet. A eighteen year old male patient reported to us with a presentation of rash with itching for three days on administration of the fixed dose combination of cefixime + ofloxacin along with paracetamol for the previous symptoms of fever with chills, headache and bodyache. Patient describes itching in the rash which is increasing. The duty doctor attended the patient and immediately stopped the further administration of the offending medication. The patient was prescribed tablet cetirizine orally along with calamine lotion for local application. The patient reported back in for follow-up and was without any residual rashes or other such complaints. He was advised to remember and cautious from the use of drugs in the offending category.


Cefixime, Fever, Petechial rash, Ofloxacin

Full Text:



Fett NCJ, Ofori AO. Evaluation of adults with cutaneous lesions of vasculitis.

Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005;209(2):123-9.

Carruthers SHG, Brian BM. Morreli’s Clinical Pharmacology Drug Therapy of Common Diseases: Problem-Based Therapeutic Decisions, 4th edn.

Sanders CC. Beta-Lactamase stability and in vitro activity of oral cephalosporins against strains possessing well-characterized mechanisms of resistance. Antimicrobial agents and chemotherapy. 1989;33(8):1313-7.

Brunton LLCB, Knollmann BC. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, Penicillins, Cephalosporins and Other β-Lactam Antibiotics, 12th edn; 2011.

Boopathy DPM, Mathew B. Method development and validation of simultaneous determination of Ofloxacin and Satranidazole in pharmaceutical dosage form by RP-HPLC. Der Pharmacia Letter. 2010;2(2):22-6.

Tanne JH. FDA adds "black box" warning label to fluoroquinolone antibiotics. Bmj 337:a816. 2008.